NICE vs RCPCH: Management of Autism Spectrum Disorder (2025)

This document provides a comparative summary for clinicians of two key UK guidelines for Autism Spectrum Disorder (ASD): the National Institute for Health and Care Excellence (NICE) guideline Autism spectrum disorder in under 19s: recognition, referral and diagnosis (CG128) and the Royal College of Paediatrics and Child Health (RCPCH) guideline Autism spectrum disorder (ASD) in children and young people: a national clinical guideline for recognition, referral, diagnosis and management. While both aim to standardise and improve care, their scope, focus, and intended audience differ significantly, leading to practical variations in implementation.

See how this translates to practice: Explore our Clinical governance features, visit the Patient Safety Hub, or review Clinical Safety & Assurance for enterprise rollout.

Scope and Audience: A Fundamental Difference

The primary distinction lies in their scope. The NICE guideline (CG128) focuses specifically on the recognition, referral, and diagnosis of ASD in people under 19. It does not provide detailed recommendations on post-diagnostic management and treatment. Conversely, the RCPCH guideline is more comprehensive, covering the entire clinical pathway from recognition and referral through to diagnosis, management, and support.

• NICE: A national standard for the diagnostic pathway, providing a framework for commissioners and providers to ensure consistent, evidence-based assessment services across England, Wales, and Northern Ireland.
• RCPCH: A practical, clinician-focused guideline for paediatricians and other child health professionals involved in the day-to-day care of autistic children and young people, applicable across the UK.

Diagnosis and Assessment

NICE CG128 Approach

NICE provides a highly structured, multi-disciplinary pathway. Key recommendations include:

• Referral: Referral to a specialist ASD team should be accepted for any child or young person where there is suspicion of ASD, without the need for a prior "wait-and-see" period.
• Assessment Team: A multi-professional team (MPT) must conduct the assessment, typically including a paediatrician, speech and language therapist, and a specialist psychologist.
• Process: The diagnostic process should include a history (developmental, medical, family), assessment of the child’s strengths and challenges across different settings (e.g., school, home), and a formal observational assessment (e.g., using the Autism Diagnostic Observation Schedule - ADOS-2).
• Co-occurring Conditions: The team should actively investigate and manage co-occurring conditions like ADHD, anxiety, or learning disabilities as part of the assessment.

RCPCH Approach

The RCPCH guideline aligns with NICE on the core principles of assessment but offers more pragmatic flexibility, acknowledging resource constraints and variations in service configuration.

• Assessment Model: It explicitly recognises different assessment models: the NICE-concordant MPT model and a paediatrician-led model with access to specialists. The latter may be necessary where full MPTs are not available, but the paediatrician must have specialist training in ASD and ensure input from key professionals like speech and language therapy is sought.
• Focus on Function: It places a strong emphasis on a functional analysis of the child's needs, moving beyond the diagnostic label to understand the impact on daily life.

Key Difference in Diagnosis

The core difference is rigidity versus pragmatism. NICE sets the ideal standard (MPT). RCPCH, while advocating for the ideal, provides a framework for safe and effective practice where the ideal MPT is not immediately available, guiding the solo practitioner or smaller teams.

Treatment and Management

NICE CG128 Limitations

As CG128's remit is the diagnostic pathway, it does not provide detailed management recommendations. It signposts to the NICE guideline Autism spectrum disorder in under 19s: support and management (NG170) for post-diagnostic care.

RCPCH Comprehensive Management

This is a major strength of the RCPCH guideline. It provides extensive, practical guidance on post-diagnostic support, including:

• Personalised Care Planning: Recommends creating a personalised plan focusing on the child’s strengths, needs, and co-occurring conditions.
• Behavioural Interventions: Advises on the use of evidence-based approaches to support behaviour that challenges, focusing on understanding the function of the behaviour and using positive behavioural support frameworks.
• Pharmacological Management: Provides clear guidance on medication, stressing it should not be used to treat the core characteristics of autism. It is only indicated for managing specific co-occurring conditions (e.g., melatonin for sleep disturbance, psychotropics for ADHD or anxiety) after non-pharmacological interventions have been tried.
• Support for Families: Emphasises the need for parent-mediated interventions, training, and emotional support.

Key Difference in Treatment

NICE CG128 is not a management guideline; RCPCH is. For a comprehensive view of treatment, clinicians must consult NG170 alongside CG128. The RCPCH document integrates diagnosis and management into a single, cohesive guide for the practising clinician.

Special Situations

Co-occurring Conditions

• NICE: Highlights the importance of identifying co-occurring conditions during assessment but offers limited management advice within CG128.
• RCPCH: Provides detailed pathways for common co-occurring conditions such as sleep disorders, feeding issues, epilepsy, ADHD, and anxiety, including assessment and stepwise management strategies.

Specific Populations (e.g., Girls, Adolescents)

• Both guidelines acknowledge the different presentation of ASD in girls and the challenges of diagnosing adolescents.
• The RCPCH guideline offers more nuanced practical advice on adapting the assessment process for these groups, discussing masking and the importance of patient-reported experiences in adolescents.

Practical Clinical Flow: A Comparative Summary

NICE Pathway

1. Recognition: Concerns raised in primary care, education, or social care.
2. Referral: Direct referral to a specialist multi-disciplinary ASD team.
3. Assessment: Comprehensive assessment by the full MPT, using standardised tools.
4. Diagnosis & Feedback: Diagnosis given by the team, followed by a detailed report and communication of findings.
5. Signposting: Family is signposted to appropriate support services and the NG170 guideline for management.

RCPCH Pathway

1. Recognition & Referral: Similar to NICE.
2. Assessment: Can be MPT-led or paediatrician-led with specialist input. Strong focus on functional impact.
3. Diagnosis & Feedback: Similar to NICE, but with immediate focus on linking diagnosis to a management plan.
4. Management & Support: The diagnosing clinician (often the paediatrician) takes a lead in initiating the personalised care plan, coordinating with local services, and managing co-occurring conditions. This provides greater continuity of care.

Practical Takeaway

The RCPCH pathway often reflects the on-the-ground reality in many NHS trusts, where paediatricians are central to the process. It provides a framework for ensuring quality even when the full NICE MPT model is not feasible.

Frequently Asked Questions (FAQs) for Clinicians

1. Which guideline should I follow if they conflict?

They rarely conflict on core principles. NICE sets the evidence-based standard for the NHS. The RCPCH guideline is designed to be NICE-concordant but offers pragmatic implementation strategies. In cases of difference, the NICE guideline typically takes precedence for service commissioning in England and Wales. However, the RCPCH advice often provides the necessary clinical detail to operationalise NICE's standards.

2. Can a paediatrician make a diagnosis alone?

According to strict NICE CG128: No, diagnosis should be made by a multi-professional team. According to RCPCH: A specialist paediatrician can make a diagnosis if they have undertaken a comprehensive assessment, including gathering information from other key professionals (especially speech and language therapy) and different settings. The RCPCH approach is a practical adaptation for services without a fully integrated MPT.

3. What is the key post-diagnostic step?

NICE (via NG170) and RCPCH strongly agree: the creation of a personalised care and support plan that moves beyond the diagnostic label to address the child's and family's specific needs, strengths, and goals.

4. How do the guidelines view medication?

Both are aligned and cautious. Medication is not for core ASD symptoms. It should only be considered for identified co-occurring conditions (e.g., ADHD, anxiety, severe sleep disorders) after environmental and psychosocial interventions have been insufficient. The RCPCH provides more specific prescribing guidance.

5. Which guideline is more useful for a practising paediatrician?

The RCPCH guideline is generally more directly useful for the day-to-day clinical practice of a paediatrician. It covers the entire patient journey from suspicion to long-term management in a single, practical document. NICE CG128 is essential for understanding the service specification and benchmark for diagnostic services.

Source Links

• NICE Guideline CG128 (June 2017, last updated December 2021): Autism spectrum disorder in under 19s: recognition, referral and diagnosis
• NICE Guideline NG170 (June 2021, last updated August 2023): Autism spectrum disorder in under 19s: support and management (Essential companion for management).
• RCPCH Clinical Guideline (2025): Autism spectrum disorder (ASD) in children and young people: a national clinical guideline